Bath Savings Trust Co trimmed its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 2.7% in the fourth quarter, Holdings Channel reports. The institutional investor owned 30,304 shares of the company’s stock after selling 845 shares during the period. Bath Savings Trust Co’s holdings in IDEXX Laboratories were worth $4,739,000 as of its most recent SEC filing.
Several other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its stake in shares of IDEXX Laboratories by 4.0% during the 2nd quarter. Vanguard Group Inc. now owns 9,264,579 shares of the company’s stock worth $1,495,488,000 after buying an additional 354,024 shares during the last quarter. BlackRock Inc. boosted its stake in shares of IDEXX Laboratories by 10.5% during the 2nd quarter. BlackRock Inc. now owns 7,100,374 shares of the company’s stock worth $1,146,142,000 after buying an additional 673,347 shares during the last quarter. Koch Industries Inc. boosted its stake in shares of IDEXX Laboratories by 44,533.1% during the 2nd quarter. Koch Industries Inc. now owns 1,399,248 shares of the company’s stock worth $1,391,000 after buying an additional 1,396,113 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of IDEXX Laboratories by 38.6% during the 2nd quarter. Renaissance Technologies LLC now owns 1,351,900 shares of the company’s stock worth $218,224,000 after buying an additional 376,300 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership boosted its stake in shares of IDEXX Laboratories by 42.8% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,310,660 shares of the company’s stock worth $211,567,000 after buying an additional 392,790 shares during the last quarter. Institutional investors own 86.61% of the company’s stock.
A number of research firms have recently commented on IDXX. Zacks Investment Research upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating and set a $184.00 price objective for the company in a research note on Tuesday, October 24th. Stifel Nicolaus restated a “buy” rating and set a $185.00 price objective on shares of IDEXX Laboratories in a research note on Tuesday, October 24th. BidaskClub upgraded shares of IDEXX Laboratories from a “sell” rating to a “hold” rating in a research note on Friday, January 5th. Aegis restated a “sell” rating on shares of IDEXX Laboratories in a research note on Friday, December 8th. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $180.00 target price on shares of IDEXX Laboratories in a research note on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $173.67.
IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, October 31st. The company reported $0.79 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.05. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. The business had revenue of $492.00 million during the quarter, compared to the consensus estimate of $492.94 million. During the same period last year, the business posted $0.62 EPS. IDEXX Laboratories’s revenue was up 9.7% on a year-over-year basis. equities research analysts anticipate that IDEXX Laboratories, Inc. will post 3.24 earnings per share for the current year.
In related news, CEO Jonathan W. Ayers sold 18,000 shares of the firm’s stock in a transaction dated Friday, November 3rd. The shares were sold at an average price of $153.75, for a total value of $2,767,500.00. Following the completion of the sale, the chief executive officer now directly owns 1,064,573 shares in the company, valued at approximately $163,678,098.75. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Jonathan W. Ayers sold 54,000 shares of the stock in a transaction dated Tuesday, November 7th. The shares were sold at an average price of $151.32, for a total transaction of $8,171,280.00. Following the completion of the transaction, the chairman now directly owns 1,064,573 shares in the company, valued at $161,091,186.36. The disclosure for this sale can be found here. Insiders sold a total of 110,000 shares of company stock valued at $16,686,200 over the last quarter. 2.77% of the stock is currently owned by company insiders.
WARNING: “Bath Savings Trust Co Sells 845 Shares of IDEXX Laboratories, Inc. (IDXX)” was published by Community Financial News and is the property of of Community Financial News. If you are reading this report on another publication, it was illegally copied and republished in violation of United States and international copyright and trademark law. The legal version of this report can be viewed at https://www.com-unik.info/2018/01/10/bath-savings-trust-co-sells-845-shares-of-idexx-laboratories-inc-idxx.html.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
What are top analysts saying about IDEXX Laboratories? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for IDEXX Laboratories and related companies.